Distinguishing recurrence and new primary tumor as well as the origin of neck metastases in head and neck cancer clinical trials by targeted DNA sequencing.
Distinguishing recurrence and new primary tumor as well as the origin of neck metastases in head and neck cancer clinical trials by targeted DNA sequencing. Acta Oncol. 2019 Jul 04;:1-3 Authors: Lilja-Fischer JK, Saksø M, Stougaard M, Steiniche T, Overgaard J PMID: 31271080 [PubMed - as supplied by publisher]
I read with interest the article “Optimized Hypofractionation Can Markedly Improve Tumor Control and Decrease Late Effects for Head and Neck Cancer” by Shuryak et al.1 Although limited to human papillomavirus–negative, radiation therapy–only cases, I believe there is still benefit in further studying this dose-fractionati on scheme. Furthermore, the article is provocative enough to suggest an “optimal” dose-fractionation regime that can extend beyond head and neck (HN) cancer.
We thank Dr. Penagaricano for his thoughtful comments and suggestions.1 Our focus is indeed on human papillomavirus –negative head and neck cancers because these are far more difficult to treat than human papillomavirus–positive tumors, where dose de-escalation might well be warranted.
ConclusionOur findings indicate that metabolic alterations, characteristic for malnutrition or cachexia, can be detected already at the beginning of the treatment, making it possible to monitor the patients with a higher risk of weight loss.
Condition: Head and Neck Cancer Interventions: Drug: AMD3100; Drug: Pembrolizumab Sponsors: Massachusetts General Hospital; Merck Sharp & Dohme Corp.; AperiSys, Inc Not yet recruiting